Comparative evaluation of two commonly administered regimens of mifepristone and misoprostol for first trimester abortion

L. Thulasi Devi, Ravi Nimonkar


Background: The objective of this study was to compare and evaluate the efficacy of two commonly administered regimens as per existing guidelines of Ministry of Health and Family Welfare for Outpatient MTP services. This study is aimed at evaluation of subjective and objective stastical benefits and side effects in performance of first trimester abortion on OPD basis in popularly used drugs as advised by MOHFW by different routes of administration. The drugs used were Tab Mifepristone (RU – 486) and Tab Misoprostol.

Methods: This prospective randomized study was conducted in Out Patient Department of Obstetrics and Gynaecology in a tertiary care hospital over a period of 1 year after due clearance was obtained from Ethical Committee. This was prospective study involving 400 ladies reporting for Outpatient MTP services within the given time period as per existing guidelines at a tertiary care hospital. Patients were assessed at the end of 7, 15and 56 days, the mean age of the patients was 24.5±0.5 and 33±1 years and treatment duration was an average of 3 days with follow up for 15 days post administration. Few cases of failure required a follow up of approximately 56 days. All patients were on follow up for a period of 3 months for determination of menstrual irregularities and contraception management.

Results: Between the 2 groups, in the sublingual Misoprostol group 100% aborted successfully at the end of 56 days. Whereas in the vaginal Misoprostol group 99% aborted successfully at the end of 56 days, only two patients requiring MVA as an OPD procedure.

Conclusions: Patients were assessed at the end of 7, 15 and 56 days and between both the groups; Mifepristone with administration of misoprostol sublingually showed better success rate in completion of procedure, quicker action with better patient satisfaction and acceptance compared to conventional administration of Mifepristone and vaginal administration of misoprostol. Misoprostol administered sublingually under medical supervision is a superior, faster abortificient and has lesser incidence of Retained Products of Conception (RPOC) or need for Suction & Evacuation (S&E) as compared to vaginal route. Side effects observed need more evaluation with larger sample size to be statistically significant.


First trimester abortion, Mifepristone, Misoprostol

Full Text:



Nothnagle M, Taylor JS. Medical methods for first – trimester abortion. Am Fam Physician. 2004;70:81-3.

Hamoda H, Flett GM. Medical termination of pregnancy in the early first trimester. J Fam Plann Reprod Health Care. 2005;31:10-4.

World Health Organization. Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertil Steril. 1991;56:32-40.

Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol. 2000;183:S44-53.

Tang OS, Schweer H, Seyberth HW, Lee SWH, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332-6.

Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88-92.

Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effect of misoprostol on uterine contractility following different routes of administration. Hum Reprod. 2004;19:81-4.

Goldberg AB, Greenberg M, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344(1):38-47.

Shannon CS, Winikoff B, eds. Misoprostol: An emerging technology for women’s health. Report of a Seminar: May 7-8, 2001. New York Population Council, 2004.

Shannon C. Misoprostol: Investigator’s Brochure. Gynuity health Projects, New York; 2006.

Sahin HG, Sahin HA, Kocer M. Randomized outpatient clinical trial of medical evacuation and surgical curettage in incomplete miscarriage. Eur J Contracept Reproductive Health Care. 2001;6(3):141-4.

Shwekerela B, Kalumuna R, Kipingili R, Mashaka N, Westheimer E, Clark W, et al. Misoprostol for treatment of incomplete abortion at the regional hospital level: Results from Tanzania. BJOG 2007;114(11):1363-7.

Diop A, Raghavan S, Rakotovao JP, Comendant R, Blumenthal PD, Winikoff B. Comparison of two routes of administration for misoprostol in the treatment of incomplete abortion: A randomised control trial. Contraception. 2009;79:456-62.

Bique C, Ustá M, Debora B, Chong E, Westheimer E, Winikoff B. Comparison of Misoprostol and manual vacuum aspiration for the treatment of incomplete abortion. Int J Gynecol Obstet. 2007;98(3):222-6.

Dao B1, Blum J, Thieba B, Raghavan S, Ouedraego M, Lankoande J, et al. Is misoprostol a safe, effective, acceptable alternative to manual vacuum aspiration for post abortion care? Results from a randomised control trial in Burkina Faso, West Africa. BJOG. 2007;114(11):1368-75.

Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, et al. A randomised trial of oral misoprostol versus manual vacuum aspiration for the treatment of incomplete abortion in Kampala, Uganda. Obstet Gynecol. 2005;106(3):540-7.

Blanchard K, Taneepanichskul S, Kiriwat O, Sirimai K, Svirirojana N, Mavimbela N, et al. Two regimens of misoprostol for treatment of incomplete abortion. Obstet Gynecol. 2004;103:860-5.

Nguyen TN, Blum J, Durocher J, Quan TT, Winikoff B. A randomised controlled study comparing 600µg versus 1200µg oral misoprostol for medical management of incomplete abortion. Contraception. 2005;72(6):438-42.

Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol. 2009;34(1):104-9.